title: A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
abstract: AML1-ETO fusion protein (AE) is generated by t(8;21)(q22;q22) chromosomal translocation, which is one of the most frequently observed structural abnormalities in acute myeloid leukemia (AML) and displays a pivotal role in leukemogenesis. The histone acetyltransferase p300 promotes self-renewal of leukemia cells by acetylating AE and facilitating its downstream gene expression as a transcriptional coactivator, suggesting that p300 may be a potential therapeutic target for AE-positive AML. However, the effects of p300 inhibitors on leukemia cells and the underlying mechanisms have not been extensively investigated. In the current study, we analyzed the anti-leukemia effects of C646, a selective and competitive p300 inhibitor, on AML cells. Results showed that C646 inhibited cellular proliferation, reduced colony formation, evoked partial cell cycle arrest in G1 phase, and induced apoptosis in AE-positive AML cell lines and primary blasts isolated from leukemic mice and AML patients. Nevertheless, no significant inhibitory effects were observed in granulocyte colony-stimulating factor-mobilized normal peripheral blood stem cells. Notably, AE-positive AML cells were more sensitive to lower C646 doses than AE-negative ones. And C646-induced growth inhibition on AE-positive AML cells was associated with reduced global histone H3 acetylation and declined c-kit and bcl-2 levels. Therefore, C646 may be a potential candidate for treating AE-positive AML.
authors: Department of Hematology, Chinese PLA General Hospital, Beijing, China.
authors: Xiao-ning
authors: XN
authors: Gao
authors: Ji
authors: J
authors: Lin
authors: Qiao-yang
authors: QY
authors: Ning
authors: Li
authors: L
authors: Gao
authors: Yu-shi
authors: YS
authors: Yao
authors: Ji-hao
authors: JH
authors: Zhou
authors: Yong-hui
authors: YH
authors: Li
authors: Li-li
authors: LL
authors: Wang
authors: Li
authors: L
authors: Yu
mesh_terms: D000107:Acetylation / Q000187:drug effects; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D059447:Cell Cycle Checkpoints / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects*; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D006657:Histones / Q000235:genetics / Q000378:metabolism; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D015514:Oncogene Proteins, Fusion / Q000235:genetics* / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics / Q000378:metabolism; D000075142:RUNX1 Translocation Partner 1 Protein; D015398:Signal Transduction / Q000187:drug effects; D050880:p300-CBP Transcription Factors / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D000099224:p300-CBP-Associated Factor
chemical_list: D050676:Core Binding Factor Alpha 2 Subunit; D004791:Enzyme Inhibitors; D016179:Granulocyte Colony-Stimulating Factor; D006657:Histones; D015514:Oncogene Proteins, Fusion; D019253:Proto-Oncogene Proteins c-bcl-2; D019009:Proto-Oncogene Proteins c-kit; D000075142:RUNX1 Translocation Partner 1 Protein; D050880:p300-CBP Transcription Factors; D000099224:p300-CBP-Associated Factor; C107844:AML1-ETO fusion protein, human
references: J Cell Sci. 2001 Jul;114(Pt 13):2363-73
references: 11559745
references: Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14059-64
references: 8943060
references: Cancer Lett. 2007 Jun 28;251(2):179-86
references: 17125917
references: Nat Med. 2002 Jul;8(7):743-50
references: 12091906
references: Cancer Cell. 2007 Nov;12(5):457-66
references: 17996649
references: Cancer Res. 2002 Nov 1;62(21):6231-9
references: 12414652
references: Blood. 2010 Jul 22;116(3):354-65
references: 20385793
references: Nat Med. 2006 Aug;12(8):945-9
references: 16892037
references: J Cell Physiol. 1999 Nov;181(2):218-30
references: 10497301
references: J Biol Chem. 2000 Aug 18;275(33):25572-6
references: 10849422
references: Cancer Sci. 2008 Aug;99(8):1523-7
references: 18754862
references: Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9506-11
references: 12881486
references: Blood. 2007 May 15;109(10):4432-40
references: 17244680
references: Oncogene. 2007 Jan 4;26(1):21-9
references: 16878158
references: Chem Biol. 2010 May 28;17(5):471-82
references: 20534345
references: Genes Dev. 2000 Jul 1;14(13):1553-77
references: 10887150
references: Trends Genet. 1998 May;14(5):178-83
references: 9613201
references: Oncogene. 2000 May 11;19(20):2430-7
references: 10828885
references: Science. 2011 Aug 5;333(6043):765-9
references: 21764752
references: Leukemia. 2001 Jan;15(1):89-94
references: 11243405
references: Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2450-5
references: 21262832
references: Mol Cancer Ther. 2011 Sep;10(9):1644-55
references: 21709130